|
| Section2 = | Section3 = | Section5 = }} Abexinostat (INN,〔(WHO Drug Information ), Vol. 25, No. 2, 2011〕 formerly PCI-24781) is an experimental drug candidate for cancer treatment.〔(Abexinostat ), NCI Cancer Dictionary〕 It is currently under development by Pharmacyclics and is in Phase II clinical trials for B-cell lymphoma.〔(Abexinostat HCl (PCI-24781), PanHDAC-inhibitor ), Pharmacyclics 〕 Pre-clinical study suggests the potential for treatment of different types of cancer as well. Abexinostat exerts its effect as a histone deacetylase inhibitor. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Abexinostat」の詳細全文を読む スポンサード リンク
|